Stilbene induced inhibition of androgen receptor dimerization: Implications for AR and ARΔLBD-signalling in human prostate cancer cells

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Streicher, Wolfgang ^a   Luedeke, Manuel ^a   Azoitei, Anca ^a   Zengerling, Friedemann ^a   Herweg, Alexander ^a   Genze, Felicitas ^a   Schrader, Mark G ^a   Schrader, Andres J ^a   Cronauer, Marcus V ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2,6 DIFLUOROSTYRYL)N,N DIMETHYLANILINE; ANDROGEN RECEPTOR; RESVERATROL; STILBENE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CANCER CELL; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CHORIOALLANTOIS; CONTROLLED STUDY; DIMERIZATION; DOWN REGULATION; ENZYME INHIBITION; FLUORESCENCE MICROSCOPY; FLUORINATION; GENE REPRESSION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; PROSTATE CANCER; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; REPORTER GENE; SIGNAL TRANSDUCTION; CHEMISTRY; DRUG EFFECTS; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

CELL LINE, TUMOR; DIMERIZATION; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; STILBENES;

EID: 84902344501     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098566     Document Type: Article

References (56)

1. Feldman BJ, Feldman D (2001) The development of androgen-Independent prostate cancer. Nat Rev Cancer 1: 34-45. (Pubitemid 33741879)
2. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ (2008) Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68: 5469-5477.
3. Mostaghel EA, Marck BT, Plymate SR, Vessella R, Balk S, et al. (2011) Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 17: 5913-5925.
4. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, et al. (2012) Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 72: 3457-3462.
5. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, et al. (2013) Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-resistant Prostate Cancer Cell Lines Cancer Res 73: 483-489.
6. Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, et al. (2013) Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 24: 1802-1807.
7. Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, et al. (2013) Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 24: 1807-1812.
8. Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, et al. (2014) Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 65: 30-36.
9. Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, et al. (2014) Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur J Cancer 50: 78-84.
10. Hörnberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, et al. (2011) Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One 6: e19059.
11. Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, et al. (2011) Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One 6: e27970.
12. Jernberg E, Thysell E, Bovinder Ylitalo E, Rudolfsson S, Crnalic S, et al. (2013) Characterization of prostate cancer bone metastases according to expression levels of steroidogenic enzymes and androgen receptor splice variants. PLoS One 8: e77407.
13. Vang O (2013) What is new for resveratrol? Is a new set of recommendations necessary? Ann N Y Acad Sci 1290: 1-11.
14. Harada N, Murata Y, Yamaji R, Miura T, Inui H, et al. (2007) Resveratrol down-regulates the androgen receptor at the post-translational level in prostate cancer cells. J Nutr Sci Vitaminol (Tokyo) 53: 556-560. (Pubitemid 351154880)
15. Wang TTY, Hudson TS, Wang T-C, Remsberg CM, Davies NM, et al. (2008) Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. Carcinogenesis 29: 2001-2010.
16. Harada N, Atarashi K, Murata Y, Yamaji R, Nakano Y, et al. (2011) Inhibitory mechanisms of the transcriptional activity of androgen receptor by resveratrol: Implication of DNA binding and acetylation of the receptor. J Steroid Biochem Mol Biol 123: 65-70.
17. Shi W, Leong M, Cho E, Farrell J, Chen H, et al. (2009) Repressive Effects of Resveratrol on Androgen Receptor Transcriptional Activity. PLoS One 4: e7398
18. Iguchi K, Toyama T, Ito T, Shakui T, Usui S, et al. (2012) Antiandrogenic activity of resveratrol analogs in prostate cancer LNCaP cells. J Androl 33: 1208-1215.
19. Zhang W, Sviripa V, Chen X, Shi J, Yu T, et al. (2013) Fluorinated N, N-dialkylaminostilbenes repress colon cancer by targeting methionine S-adenosyl-transferase 2A. ACS Chem Biol 8: 796-803.
20. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S et al. (1994). Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 57: 406-212.
21. Schütz SV, Schrader AJ, Zengerling F, Genze F, Cronauer MV, et al. (2011) Inhibition of glycogen synthase kinase-3b counteracts ligand-independent activity of the androgen receptor in castration resistant prostate cancer. PLoS One 6: e25341.
22. Kuefer R, Hofer MD, Altug V, Zorn C, Genze F, et al. (2004) Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br J Cancer 90: 535-541. (Pubitemid 38258278)
23. Dias SJ, Li K, Rimando AM, Dhar S, Mizuno CS, et al. (2013) Trimethoxy-resveratrol and piceatannol administered orally suppress and inhibit tumor formation and growth in prostate cancer xenografts. Prostate 73: 1135-1146.
24. Mitchell SH, Zhu W, Young CY (1999) Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res 59: 5892-5895. (Pubitemid 30004946)
25. Zhang W, Sviripa V, Kril LM, Chen X, Yu T, et al. (2011) Fluorinated N, N-Dialkylaminostilbenes for Wnt Pathway Inhibition and Colon Cancer Repression. J Med Chem 54: 1288-1297.
26. Hsieh TC, Wu JM (1999) Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp Cell Res 249: 109-115.
27. Hsieh TC, Wu JM (2000) Grape-derived chemopreventive agent resveratrol decreases prostate-specific antigen (PSA) expression in LNCaP cells by an androgen receptor (AR)-independent mechanism. Anticancer Res 20: 225-228.
28. Haile S, Sadar MD (2011) Androgen receptor and its splice variants in prostate cancer. Cell Mol Life Sci 68: 3971-3981.
29. Guo Z, Yang X, Sun F, Jiang R, Linn DE, et al. (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69: 2305-2313.
30. Streicher W, Zengerling F, Laschak M, Weidemann W, Höpfner M, et al. (2012) AR-Q640X, a model to study the effects of constitutively active C-terminally truncated AR variants in prostate cancer cells. World J Urol 30: 333-339.
31. Sun S, Sprenger CCT, Vessella RL, Haugk K, Soriano K, et al. (2010) Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120: 2715-2730.
32. van Royen ME, van Cappellen WA, de Vos C, Houtsmuller AB, Trapman J (2012). Stepwise androgen receptor dimerization. J Cell Sci 125: 1970-1979.
33. Amri A, Chaumeil JC, Sfar S, Charrueau C (2012) Administration of resveratrol: What formulation solutions to bioavailability limitations? J Control Release 158: 182-193.
34. Cai C, Balk SP (2011) Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer 18: R175-182.
35. Jenster G, van der Korput HA, van Vroonhoven C, van der Kwast TH, Trapman J, et al. (1991) Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 5: 1396-1404.
36. Céraline J; Cruchant MD, Erdmann E, Erbs P, Kurtz JE, et al. (2004) Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer. Int J Cancer 108: 152-157. (Pubitemid 37444458)
37. Tepper CG, Boucher DL, Ryan PE, Ma A-H, Xia L, et al. (2002) Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 62: 6606-6614. (Pubitemid 35364127)
38. Mudryj M, Tepper CG (2013) On the origins of the androgen receptor low molecular weight species. Horm Cancer 4: 259-269.
39. Libertini SJ, Tepper CG, Rodriguez V, Asmuth DM, Kung H-J, et al. (2007) Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. Cancer Res 67: 9001-9005. (Pubitemid 47535881)
40. Chen H, Libertini SJ, George M, Dandekar S, Tepper CG, et al. (2010) Genome-wide analysis of androgen receptor binding and gene regulation in two CWR22-derived prostate cancer cell lines. Endocr Relat Cancer 17: 857-873.
41. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, et al. (2010) Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 107: 16759-16765.
42. Chan SC, Li Y, Dehm SM (2012) Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J Biol Chem 287: 19736-19749.
43. Li X, Liu Z, Xu X, Blair CA, Sun Z, et al. (2012) Kava components down-regulate expression of AR and AR splice variants and reduce growth in patient-derived prostate cancer xenografts in mice. PLoS One 7: e31213.
44. Yamashita S, Lai KP, Chuang KL, Xu D, Miyamoto H, et al. (2012) ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia 14: 74-83.
45. Laschak M, Spindler KD, Schrader AJ, Hessenauer A, Streicher W, et al. (2012) JS-K, a glutathione/glutathione S-transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cells. BMC Cancer 12: 130.
46. Sadar MD (2012) Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer. World J Urol.30: 311-318.
47. Sadar MD, Williams DE, Mawji NR, Patrick BO, Wikanta T, et al. (2008). Sintokamides A to E, chlorinated peptides from the sponge Dysidea sp. that inhibit transactivation of the N-terminus of the androgen receptor in prostate cancer cells. Org Lett 10: 4947-4950.
48. Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, et al. (2010) Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the aminoterminus domain of the androgen receptor. Cancer Cell. 2010: 17: 535-546.
49. Meimetis LG, Williams DE, Mawji NR, Banuelos CA, Lal AA, et al. (2012) Niphatenones, glycerol ethers from the sponge Niphates digitalis block androgen receptor transcriptional activity in prostate cancer cells: structure elucidation, synthesis, and biological activity. J Med Chem 55: 503-514.
50. Reid J, Kelly SM, Watt K, Price NC, McEwan IJ (2002) Conformational analysis of the androgen receptor amino-terminal domain involved in transactivation. Influence of structure-stabilizing solutes and protein-protein interactions. J Biol Chem 277: 20079-20086. (Pubitemid 34975644)
51. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337-342. (Pubitemid 44764104)
52. Cronauer MV, Ince Y, Engers R, Rinnab L, Weidemann W, et al. (2007) Nitric oxide-mediated inhibition of androgen receptor activity: possible implications for prostate cancer progression. Oncogene 26(13): 1875-1884. (Pubitemid 46474631)
53. Rinnab L, Schütz SV, Diesch J, Schmid E, Küfer R, et al. (2008) Inhibition of glycogen synthase kinase-3 in androgen-responsive prostate cancer cell lines: are GSK inhibitors therapeutically useful? Neoplasia. 10: 624-634.
54. Schütz SV, Cronauer MV, Rinnab L (2010) Inhibition of glycogen synthase kinase-3beta promotes nuclear export of the androgen receptor through a CRM1-dependent mechanism in prostate cancer cell lines. J Cell Biochem 109: 1192-1200.
55. Kemper JK, Xiao Z, Ponugoti B, Miao J, Fang S, et al. (2009) FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. Cell Metab 10: 392-404.
56. Jones SB, DePrimo SE, Whitfield ML, Brooks JD (2005) Resveratrol-induced gene expression profiles in human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 14: 596-604. (Pubitemid 40489201)